AVEO Oncology is passionate in our pursuit of improving the lives of patients with cancer.
Find out More
A Phase 3 Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC
Click here for more information
2016 JMP Securities Life Science Conference
June 22, 2016
28th Annual ROTH Conference
March 16, 2016
AVEO Initiates the Evaluation of Tivozanib in Combination with Bristol-Myers Squibb’s Opdivo® (nivolumab) in Advanced Renal Cell Carcinoma
August 15, 2016
AVEO Oncology Reports Second Quarter 2016 Financial Results and Provides Business Update
August 4, 2016
AVEO to Present at the 2016 JMP Securities Life Science Conference
June 15, 2016
© 2016 AVEO Pharmaceuticals, Inc. All rights reserved.